title: Naproxen ophthalmic solution to manage inflammation after phacoemulsification.
abstract: OBJECTIVE
  To explore the efficacy and safety of 2 concentrations (0.1% and 0.2%) of sodium naproxen ophthalmic solution in controlling ocular inflammation in patients having phacoemulsification and intraocular lens implantation.
  
  
  METHODS
  Service d'Ophtalmologie La Pitie' and Centre Ophtalmologique, Paris, and Clinique Sourdille, Nantes, France; Department of Ophthalmology, University of Lausanne, Switzerland.
  
  
  METHODS
  One hundred one patients were randomly treated with naproxen 0.1%, naproxen 0.2%, or diclofenac 0.1% 3 times a day for 30 days starting the day before surgery. Postsurgical ocular inflammation was measured after 1, 10, and 30 days using the Kowa FC-1000 laser flare-cell meter and a conventional slitlamp biomicroscope. Safety parameters were evaluated at the same visits.
  
  
  RESULTS
  Naproxen 0.2% ophthalmic solution and diclofenac 0.01% were comparable in controlling postsurgical inflammation. The naproxen was well tolerated. No serious adverse events occurred during the study.
  
  
  CONCLUSIONS
  These preliminary results suggest that naproxen ophthalmic solution may be effectively and safely used to control inflammation after uneventful phacoemulsification. Because of the limited number of patients, larger studies are needed to confirm these results.
authors.affiliation: Medical Department SIFI S.p.A, Lavinaio-Catania, Italy. vincenzo_papa@sifi.it
authors.forename: Vincento
authors.initials: V
authors.lastname: Papa
authors.forename: Giovanni
authors.initials: G
authors.lastname: Milazzo
authors.forename: Marcello
authors.initials: M
authors.lastname: Santocono
authors.forename: Valerie
authors.initials: V
authors.lastname: Servolle
authors.forename: Philippe
authors.initials: P
authors.lastname: Sourdille
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Santiago
authors.forename: Jacques
authors.initials: J
authors.lastname: Darondeau
authors.forename: Nathalie
authors.initials: N
authors.lastname: Cassoux
authors.forename: Phuc
authors.initials: P
authors.lastname: LeHoang
mesh_terms: D000867:Anterior Chamber / Q000473:pathology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D004008:Diclofenac / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D009288:Naproxen / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D010149:Postoperative Pain / Q000188:drug therapy / Q000209:etiology; D018918:Phacoemulsification / Q000009:adverse effects*; D011446:Prospective Studies; D012449:Safety; D014606:Uveitis, Anterior / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions; D004008:Diclofenac; D009288:Naproxen